RTP Mobile Logo
Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Non-Hodgkin Lymphoma (Webinar Audio Proceedings)
Released October 2021

Featuring perspectives from Drs Andrew Evens, Ian Flinn and Gilles Salles. Published October 22, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas.

    LEARNING OBJECTIVES

    • Understand published research data informing the selection, sequencing and combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
    • Consider patient age, performance status, and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
    • Assess available clinical trial findings informing the use of CD19-directed CAR (chimeric antigen receptor) T-cell therapies for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
    • Recognize and manage the side effects and toxicities associated with existing and recently approved systemic therapies for FL, DLBCL and MCL to support quality of life and continuation of treatment.
    • Recall new data with investigational agents and strategies demonstrating promising activity in various non-Hodgkin lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2021/NHL/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SOHO2021/NHL/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2021/NHL/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SOHO2021/NHL.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Andrew M Evens, DO, MSc
    Associate Vice Chancellor, Clinical Innovation and Data Analytics
    Rutgers Biomedical and Health Sciences, Rutgers University
    Associate Director (Clinical Services), Rutgers Cancer Institute of New Jersey
    Professor of Medicine, Rutgers Robert Wood Johnson Medical School
    System Director of Medical Oncology, and Oncology Lead for the Combined Medical Group, RWJBarnabas Health
    New Brunswick, New Jersey

    Advisory Committee: Epizyme Inc, HUTCHMED, Karyopharm Therapeutics, Miltenyi Biotec, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Consulting Agreements: COTA, Curio Science, Patient Power; Data and Safety Monitoring Board/Committee: AbbVie Inc, Novartis, Pharmacyclics LLC, an AbbVie Company.

    Ian W Flinn, MD, PhD
    Director of Lymphoma Research Program
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements (All payments to institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Great Point Partners LLC, Hutchison MediPharma, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Unum Therapeutics, Verastem Inc, Vincerx Pharma, YL-Pharma Co Ltd; Contracted Research (All payments to institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Accelerator, Unum Therapeutics, Verastem Inc.

    Gilles Salles, MD, PhD
    Service Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc: Consulting Agreements: Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc..

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Novartis and TG Therapeutics Inc.

    Release date: October 2021
    Expiration date: October 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):